Featured White Papers
Technology Industry
Industry: Email Alert RSS FeedBioStratum Inc
BT Catalyst, Sept, 2002
BioStratum Inc. of Research Triangle Park has received Fast Track status from the FDA for Pyridorin[TM], its lead drug candidate for diabetic kidney disease. To receive the status, a drug candidate must be intended for the treatment of a serious or life-threatening condition, and demonstrate the potential to address significant unmet medical needs for the condition.
Pyridorin[TM] is in Phase II clinical trials.
COPYRIGHT 2002 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning